Cancer Vaccine Finally Here? Moderna's mRNA Therapy Achieves Phase 3 Success, Potential Market Launch by 2027

The global recognition of mRNA vaccine technology, sparked by the COVID-19 pandemic, may now be leading to another major breakthrough—this time in the fight against cancer. According to Reuters, U.S. pharmaceutical companies Moderna and Merck (known as MSD outside the U.S.) have announced that their jointly developed personalized mRNA cancer therapy, intismeran autogene (V940/mRNA-4157), achieved positive results in a Phase 3 clinical trial for high-risk melanoma, successfully meeting its primary endpoint.

This result is seen as a significant milestone for mRNA-based cancer therapies. However, this so-called 'cancer vaccine' differs fundamentally from preventive vaccines for influenza or COVID-19. It is not a one-shot solution for healthy individuals to prevent all cancers. Instead, it is designed for patients who have already been diagnosed with cancer, undergone tumor removal surgery, and remain at risk of recurrence. The therapy involves analyzing each patient’s unique tumor mutations and creating a customized treatment plan.

Moderna's Cancer Vaccine Succeeds in Phase 3 Trial: Reduces Melanoma Recurrence and Metastasis Risk

On August 19, Moderna and Merck announced results from the Phase 3 INTERPATH-001 trial, which enrolled 1,137 high-risk patients with Stage IIB to IV cutaneous melanoma who had completed surgical resection. Participants were randomized in a 2:1 ratio: one group received intismeran in combination with the immunotherapy drug Keytruda (pembrolizumab), while the other received Keytruda alone.

The results showed that, in a pre-specified interim analysis, the combination therapy group demonstrated statistically significant improvements in both 'recurrence-free survival' (RFS) and 'distant metastasis-free survival' (DMFS) compared to the Keytruda-only group. These improvements met both statistical significance and the clinically meaningful thresholds defined in the study. Moderna emphasized that this marks the first time a personalized neoantigen therapy has achieved positive results in a Phase 3 clinical trial, and the first such milestone for an mRNA cancer therapy.

However, the companies have only released preliminary results so far, and full data—including detailed risk ratios and actual recurrence rates—have not yet been disclosed. The trial will continue to follow patients to determine whether the combination therapy can ultimately extend 'overall survival' (OS).

How Is the Cancer Vaccine Made? A Unique Treatment for Each Patient

The most distinctive feature of this therapy is its 'one patient, one treatment' approach. Medical teams analyze the genetic mutations specific to a patient’s tumor using tissue removed during surgery. From these mutations, they select suitable 'neoantigens'—tumor-specific markers that the immune system can recognize—and then manufacture an mRNA therapy tailored to the individual’s tumor profile.

According to Moderna and Merck, each dose of intismeran can encode up to 34 different tumor neoantigens. Once injected into the body, the mRNA instructs cells to produce these corresponding antigens, effectively 'teaching' the immune system to recognize the unique mutations present in cancer cells and activating T cells to attack them.

This represents a key difference from traditional chemotherapy. While chemotherapy works by killing rapidly dividing cells, the concept behind personalized cancer vaccines is to train the immune system to identify 'this patient’s specific cancer cells.' In this study, Keytruda is used in combination to block cancer cells’ ability to suppress the immune system, aiming to enhance the immune cells’ attack.

Phase 2 Five-Year Follow-Up Also Shows Benefits: 49% Reduction in Recurrence or Death Risk

In fact, this therapy has shown promising results before. The five-year follow-up data from the Phase 2b trial, released in June, showed that intismeran combined with Keytruda reduced the risk of cancer recurrence or death by 49% and the risk of distant metastasis or death by 59%, compared to Keytruda alone.

Regarding safety, the preliminary Phase 3 results revealed no new safety concerns. Earlier Phase 2b five-year data indicated that common treatment-related adverse events in the combination group included fatigue, injection site pain, and chills, mostly classified as Grade 1 or 2. However, a full assessment of the therapy’s benefit-risk profile will require the complete Phase 3 data.

When Will the Cancer Vaccine Be Available? Key Hurdles Remain

Following the trial success, one of the biggest questions from the market is when patients will actually be able to access this therapy. Moderna and Merck stated they plan to present detailed data at upcoming international medical conferences and share results with regulatory agencies. However, they have not yet announced specific timelines for regulatory submissions, approvals, or market launch.

Reuters cited Jefferies analyst Andrew Tsai, who estimated that if regulatory processes proceed smoothly, the personalized mRNA cancer vaccine for melanoma could reach the market by 2027.

Additionally, because each dose must be individually analyzed, designed, and manufactured based on a patient’s unique tumor mutations, future commercialization will depend on overcoming key challenges: shortening manufacturing time, scaling up production capacity, and controlling costs. Analysts also caution that full Phase 3 data has not yet been released, and overall survival outcomes remain under follow-up.

Not Just Melanoma! Trials Ongoing for Lung, Bladder, and Kidney Cancers

More importantly, Moderna and Merck are not limiting their mRNA cancer therapy development to melanoma alone. The current INTERPATH development program includes nine Phase 2 and Phase 3 clinical trials covering melanoma, non-small cell lung cancer, bladder cancer, and renal cell carcinoma. Early-stage research is also underway for pancreatic and gastric cancers.

Therefore, the true breakthrough here is not that humanity has found a 'universal vaccine' to prevent all cancers with a single shot. Rather, it demonstrates that personalized mRNA therapies, designed based on individual tumor mutations, have successfully crossed a critical threshold in a large-scale Phase 3 trial for the first time. If subsequent full data, overall survival results, and regulatory reviews proceed smoothly, cancer treatment may indeed be moving toward a highly personalized era—where every patient receives a treatment uniquely tailored to them.